TORONTO–(BUSINESS WIRE)–The More Life Company Corp. (the “Company” or “MLCO”), (CSE: MLCO) (OTC: TMLCF), is pleased to announce results from an exploratory eight-participant human pharmacokinetic study conducted with third-party medical personnel to evaluate United States Pharmacopeia (“USP”) grade testosterone formulated using the Company’s patented Quicksome™ sublingual delivery technology. The study showed rapid systemic appearance of USP testosterone following Quicksome administration, wi